About The Study: In extremely preterm infants with a protocol-defined patent ductus arteriosus, death or bronchopulmonary dysplasia did not differ between the expectant management group and the active treatment group. Survival was substantially higher with expectant management.
Corresponding Author: To contact the corresponding author, Matthew M. Laughon, MD, MPH, email matt_laughon@med.unc.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2025.23330)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the Hot Topics in Neonatology 45th Annual Conference.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.23330?guestAccessKey=fac49601-448f-4dfa-8fce-05a66f03f1c9&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=120925
JAMA